Newsroom | 38667 results

Sorted by: Latest

Medical Devices
-

Parse Biosciences lance son kit Evercode Whole Blood Fixation

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, l'un des principaux fournisseurs de solutions de séquençage monocellulaire accessibles et évolutives, annonce aujourd'hui le lancement d'Evercode™ Whole Blood Fixation, un nouveau kit qui permet la fixation immédiate du sang total directement au point de prélèvement. La technologie élimine le besoin d'isolement des PBMC sur site, d'équipement spécialisé ou de personnel qualifié, permettant aux équipes de recherche en hématologie translationnelle et p...
-

Nihon Kohden Brings Advanced EEG Technology Built on 70 Years of Innovation to Booth #725 at the American Epilepsy Society 2025 Annual Meeting

IRVINE, Calif.--(BUSINESS WIRE)--Nihon Kohden, a global leader in neurodiagnostic technology, will showcase its integrated EEG portfolio at the American Epilepsy Society (AES) 2025 Annual Meeting, held December 5–9 in Atlanta. Attendees are invited to Booth #725 to explore solutions shaped through extensive collaboration with the clinicians who use them—bringing together mobility, connectivity and performance to advance neurological care. With a history of advancing EEG technology that predates...
-

Aptar Named One of America’s Most Responsible Companies by Newsweek for the Seventh Consecutive Year

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Named One of America’s Most Responsible Companies by Newsweek for the Seventh Consecutive Year...
-

IDEX Corporation Appoints Sean Gillen as SVP, Chief Financial Officer

NORTHBROOK, Ill.--(BUSINESS WIRE)--IDEX Corporation announces Sean M. Gillen as Senior Vice President and Chief Financial Officer, effective January 5, 2026....
-

Baxter Announces Pricing of Tender Offers for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the consideration payable in connection with the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The table below sets forth the Total Consideration (as defined below) for each series of Notes. Title of Security CUSIP Number(1) Principal Amount Outstanding U.S. Treasury Reference Security Bloomberg Reference Page Reference Yield Fix...
-

Open Letter to SNMMI Board of Directors and President Dr. Prabhu Ethiraj: TeamBest Global Calls for Strengthened Collaboration to Advance Theranostics and Expand Cancer Diagnosis and Treatment Options

WASHINGTON--(BUSINESS WIRE)--Dr. Krishnan Suthanthiran, President/Founder of TeamBest Global (TBG) companies and the International Society for Radiation Medicine & Molecular Imaging (ISRMMI), is urging closer collaboration with the Society of Nuclear Medicine and Molecular Imaging (SNMMI) to accelerate the adoption of theranostics and broaden treatment options for cancer patients worldwide. TBG has long been recognized for developing cost-effective, innovative technologies, and advanced the...
-

SAI MedPartners Enhances Its Competitive Intelligence Capabilities Through the Acquisition of The Dunn Group

READING, Pa.--(BUSINESS WIRE)--SAI MedPartners (“SAI”), a global consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries, is pleased to announce that it has acquired The Dunn Group (“TDG”). Northlane Capital Partners (“NCP”) partnered with management to acquire SAI in June 2022. TDG, headquartered in Totowa, NJ, is a competitive intelligence firm that focuses on providing primary business intelligence to clients in the pharmaceu...
-

VALVOSOFT®, le premier traitement non invasif de la Sténose Aortique Sévère symptomatique (sSAS) développé par Cardiawave, obtient le marquage CE

LEVALLOIS-PERRET, France--(BUSINESS WIRE)--Cardiawave, medtech pionnière du développement d’une thérapie par ultrasons non invasive (NIUT) pour la sténose aortique, a reçu le certificat CE pour Valvosoft®, la première alternative thérapeutique non invasive au monde, pour le traitement de la sténose aortique sévère symptomatique (sSAS), une maladie grave, dégénérative, en forte croissance en raison du vieillissement de la population, et pour laquelle de nombreux patients dans le monde restent sa...
-

VALVOSOFT®, the First Non-Invasive Treatment for Severe Symptomatic Aortic Stenosis (sSAS) from Cardiawave Receives CE Marking

LEVALLOIS-PERRET, France--(BUSINESS WIRE)--Cardiawave, a pioneering medtech company developing non-invasive ultrasound therapy (NIUT) for aortic stenosis, has received CE Certificate for Valvosoft®, the world’s first non-invasive therapeutic alternative to treat Severe Symptomatic Aortic Stenosis (sSAS), a serious, degenerative and fast-growing disease due to population aging, which remains without a solution for many patients around the world. “Innovating to address unmet patient needs is at t...
-

Spatial OMICS Market Intelligence Report 2025-2030: Rising Global R&D Investments Driving the Industry at 7.58% CAGR - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Spatial OMICS Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030" has been added to ResearchAndMarkets.com's offering. The Global Spatial OMICS Market, valued at USD 298.81 Million in 2024, is projected to experience a CAGR of 7.58% to reach USD 463.22 Million by 2030. This market's expansion is primarily driven by continuous advancements in sequencing and imaging platforms, a rising imperative for precision medicine in diagnostics...